Sapu Nano Unveils First-in-Human Clinical Trial of Sapu-003 at 8th Australian Translational Breast Cancer Research Symposium

Core Insights - Sapu Nano has announced the initiation of a Phase 1 study for Sapu-003, a novel intravenous formulation of everolimus using Deciparticle™ technology, aimed at improving treatment for advanced cancers [1][2] Company Overview - Sapu Nano is part of the Sapu family of companies, established through a joint venture between Oncotelic Therapeutics, Inc. and Dragon Overseas Capital Limited [1] - Oncotelic Therapeutics focuses on developing oncology and immunotherapy products, addressing high unmet needs in cancer treatment [5][6] Product Development - Sapu-003 is the first intravenous Deciparticle™ formulation of everolimus, which is an mTOR inhibitor used in oncology [2] - The oral version of everolimus has limitations due to low bioavailability and gastrointestinal toxicities, which Sapu-003 aims to overcome [2] Clinical Trial Details - The Phase 1 trial is being conducted in collaboration with SOCRU, Ingenū, and Medicilon, ensuring robust clinical execution and regulatory alignment [3] - The trial is open for enrollment at leading oncology centers in Australia, targeting adults with advanced HR+/HER2– breast cancer or other mTOR-sensitive tumors [4] Strategic Partnerships - The collaboration with SOCRU, Ingenū, and Medicilon is expected to accelerate the development of Sapu-003 and enhance its delivery to patients [5]